Correlation Between FibroGen and Puma Biotechnology

Can any of the company-specific risk be diversified away by investing in both FibroGen and Puma Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining FibroGen and Puma Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between FibroGen and Puma Biotechnology, you can compare the effects of market volatilities on FibroGen and Puma Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in FibroGen with a short position of Puma Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of FibroGen and Puma Biotechnology.

Diversification Opportunities for FibroGen and Puma Biotechnology

-0.36

Correlation Coefficient

FibroGen  Puma Biotechnology

Very good diversification

The 3 months correlation between FibroGen and Puma is -0.36. Overlapping area represents the amount of risk that can be diversified away by holding FibroGen and Puma Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Puma Biotechnology and FibroGen is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on FibroGen are associated (or correlated) with Puma Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Puma Biotechnology has no effect on the direction of FibroGen i.e., FibroGen and Puma Biotechnology go up and down completely randomly.

Pair Corralation between FibroGen and Puma Biotechnology

Given the investment horizon of 90 days FibroGen is expected to under-perform the Puma Biotechnology. In addition to that, FibroGen is 1.89 times more volatile than Puma Biotechnology. It trades about -0.05 of its total potential returns per unit of risk. Puma Biotechnology is currently generating about 0.03 per unit of volatility. If you would invest  315.00  in Puma Biotechnology on December 26, 2024 and sell it today you would earn a total of  10.00  from holding Puma Biotechnology or generate 3.17% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

FibroGen  vs.  Puma Biotechnology

FibroGen

Risk-Adjusted Performance

Very Weak

Over the last 90 days FibroGen has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Puma Biotechnology

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Puma Biotechnology are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite fairly unsteady basic indicators, Puma Biotechnology may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Pair Trading with FibroGen and Puma Biotechnology

The main advantage of trading using opposite FibroGen and Puma Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if FibroGen position performs unexpectedly, Puma Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Puma Biotechnology will offset losses from the drop in Puma Biotechnology's long position.

The idea behind FibroGen and Puma Biotechnology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.